The effects of sargramostim and filgrastim on hematopoietic cells are described. Filgrastim is a lineage-specific colonystimulating factor (CSF), mainly affecting neutrophils. In addition to enhancing ...

Stroke remains a leading cause of morbidity worldwide, with limited pharmacological options beyond thrombolysis and thrombectomy in the acute phase. Granulocyte colony-stimulating factor (G-CSF), a ...

Impact of an Interdisciplinary Goals-of-Care Program Among Medical Inpatients at a Comprehensive Cancer Center During the COVID-19 Pandemic: A Propensity Score Analysis TrACER was a cluster randomized ...

Retinal detachment (RD) triggers a neuroinflammatory response aimed at clearing damaged photoreceptors (PR) and limiting injury. However, this response can unintentionally worsen retinal ...

Reducing inpatient mortality in patients with cancer through multidisciplinary review and targeted interventions. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract ...

A pilot study has suggested that intense physical exercise may mobilise a smaller but more targeted population of blood stem ...

Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmune diseases, today announced positive interim ...

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant colony-stimulating factor 1 receptor ...

29 Phase I Stage III/IV melanoma pts (16) Intradermal injection of sargramostim into melanoma lesions and normal skin (as a control) for 10 days at four dose levels (10, 20, 40, and 80 µg/day) ...